Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Inclusion Criteria: * patient compliance is good, the research process of this study can be understood, and written informed consent is signed; * Age ≥ 18 years old, ≤ 75 years old; * Histologically or cytologically confirmed pancreatic adenocarcinoma； * no prior treatment; * Based on imaging findings, MDT decided patients intoborderline resectable (group A) or unresectable (group B) (according to the resectability assessment criteria in the 2018 Pancreatic Cancer Comprehensive Care Guidelines); * ECOG\<2; * Bone marrow function: hemoglobin (HGB) ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelets (PLT) ≥ 100 × 109 / L; * Liver function: ALT, AST ≤ 2.5 × upper limit of normal (ULN), if there is liver metastasis, ALT, AST ≤ 5 × ULN; serum total bilirubin \< 1.5 × ULN; * Renal function: serum creatinine is within normal range; * Patients without biliary obstruction, patients requiring biliary stent implantation must be completed at least 7 days prior to enrollment; * Non-pregnant and lactating women, women of reproductive age/male should take effective contraceptive measures during the study period and within 6 months after the end of the study treatment; * No contraindication to the use of S-1and albumin-bound paclitaxel. Exclusion Criteria: * Patients who have had other malignant tumors within 5 years (except for cured cervical cancer in situ or non-melanoma skin cancer); * Interstitial pneumonia or pulmonary fibrosis; * Severe pleural effusion or ascites; * Watery diarrhea; * There are serious concomitant diseases: such as HIV-positive,chronic HBV/HCV in active period, people who have diabetes and poorly controlled by hypoglycemic drugs, clinically severe (ie, active) heart disease, uncontrolled epilepsy, central nervous system disease or mental disorder; * Current or previous patients with grade II peripheral neuropathy; * Abnormal digestive tract or metabolic function, which may affect the s-1 absorber; * Participated in other clinical researchers within 4 weeks prior to enrollment; * Patients who have undergone organ transplantation; * Patients considered by the investigator to be unfit for this trial.